🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Metformin for the Treatment of Microvascular Dysfunction After Gestational Diabetes

RecruitingEARLY Phase 1Ages 18 Years - 45 YearsFemaleAnna Stanhewicz, PhD
NCT05917587 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this investigation is to examine the mechanisms mediating vascular dysfunction in women who have had gestational diabetes and how metformin may be a valuable treatment tool to improve microvascular function in these women before the onset of disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * ≥12 weeks and ≤5 years postpartum * history of GDM or healthy pregnancy Exclusion Criteria: * prediabetes or diabetes (HbA1c ≥5.7%) * current tobacco use * cardiovascular or metabolic disease * cardiovascular or metabolic medication * history of hypertension during pregnancy * current pregnancy
💊

What it tests

  • Metformin Hydrochloride
  • placebo
📍

Where

1 site
University of Iowa
Iowa City, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy